10x Genomics [TXG] vs Schrodinger [SDGR] Detailed Stock Comparison

10x Genomics

NASDAQ
Loading...

Schrodinger

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: 10x Genomics wins in 15 metrics, Schrodinger wins in 3 metrics, with 0 ties. 10x Genomics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric10x GenomicsSchrodingerBetter
P/E Ratio (TTM)-8.5544.3910x Genomics
Price-to-Book Ratio2.054.4210x Genomics
Debt-to-Equity Ratio11.2233.3810x Genomics
PEG Ratio0.05-2.19Schrodinger
EV/EBITDA-11.07-6.3310x Genomics
Profit Margin (TTM)-13.13%-76.22%10x Genomics
Operating Margin (TTM)-2.63%-96.61%10x Genomics
Return on Equity-11.30%-44.40%10x Genomics
Return on Assets (TTM)-9.45%-17.52%10x Genomics
Free Cash Flow (TTM)$-6.73M$-164.68M10x Genomics
1-Year Return-28.66%14.09%Schrodinger
Price-to-Sales Ratio (TTM)2.466.3710x Genomics
Enterprise Value$1.23B$1.18B10x Genomics
EV/Revenue Ratio1.904.9610x Genomics
Gross Profit Margin (TTM)72.34%47.77%10x Genomics
Revenue per Share (TTM)$5$310x Genomics
Earnings per Share (Diluted)$-0.70$-2.4810x Genomics
Beta (Stock Volatility)2.051.74Schrodinger
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

10x Genomics vs Schrodinger Stock Performance Analysis

Loading Price Chart...

10x Genomics
Schrodinger
10x Genomics Stock Overview | Schrodinger Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
10x Genomics-8.23%-0.77%-16.73%-2.68%53.03%-18.25%
Schrodinger-5.31%0.50%3.70%-2.28%10.71%-1.18%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
10x Genomics-28.66%-54.65%-92.91%-77.81%-77.81%-77.81%
Schrodinger14.09%-7.99%-65.21%-36.84%-36.84%-36.84%

News Based Sentiment: 10x Genomics vs Schrodinger

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Schrodinger

News based Sentiment: MIXED

Schrodinger experienced a blend of positive and negative developments in October. While the Q2 earnings beat and analyst upgrade were encouraging, the stock's volatility, mixed analyst ratings, and continued unprofitability create a complex investment picture. The company's future success depends heavily on its drug pipeline and software business growth.

View Schrodinger News Sentiment Analysis

Performance & Financial Health Analysis: 10x Genomics vs Schrodinger

MetricTXGSDGR
Market Information
Market Cap i$1.59B$1.52B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i2,746,6601,092,130
90 Day Avg. Volume i2,469,4201,035,247
Last Close$11.60$20.16
52 Week Range$6.78 - $20.92$16.60 - $28.47
% from 52W High-44.55%-29.19%
All-Time High$208.99 (Jun 28, 2021)$117.00 (Feb 22, 2021)
% from All-Time High-94.45%-82.77%
Growth Metrics
Quarterly Revenue Growth0.13%0.16%
Quarterly Earnings Growth0.13%0.16%
Financial Health
Profit Margin (TTM) i-0.13%-0.76%
Operating Margin (TTM) i-0.03%-0.97%
Return on Equity (TTM) i-0.11%-0.44%
Debt to Equity (MRQ) i11.2233.38
Cash & Liquidity
Book Value per Share (MRQ)$6.21$4.66
Cash per Share (MRQ)$3.59$6.12
Operating Cash Flow (TTM) i$66.95M$27.50M
Levered Free Cash Flow (TTM) i$58.22M$-6,255,750
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 10x Genomics vs Schrodinger

MetricTXGSDGR
Price Ratios
P/E Ratio (TTM) i-8.5544.39
Forward P/E i-10.45-8.34
PEG Ratio i0.05-2.19
Price to Sales (TTM) i2.466.37
Price to Book (MRQ) i2.054.42
Market Capitalization
Market Capitalization i$1.59B$1.52B
Enterprise Value i$1.23B$1.18B
Enterprise Value Metrics
Enterprise to Revenue i1.904.96
Enterprise to EBITDA i-11.07-6.33
Risk & Other Metrics
Beta i2.051.74
Book Value per Share (MRQ) i$6.21$4.66

Financial Statements Comparison: 10x Genomics vs Schrodinger

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TXGSDGR
Revenue/Sales i$154.88M$59.55M
Cost of Goods Sold i$49.44M$28.43M
Gross Profit i$105.45M$31.12M
Research & Development i$64.25M$45.84M
Operating Income (EBIT) i$-48.53M$-50.89M
EBITDA i$-32.89M$-36.21M
Pre-Tax Income i$-33.51M$-59.78M
Income Tax i$852,000$28,000
Net Income (Profit) i$-34.36M$-59.81M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TXGSDGR
Cash & Equivalents i$377.06M$326.00M
Total Current Assets i$579.73M$570.94M
Total Current Liabilities i$107.90M$165.47M
Long-Term Debt i$70.63M$99.41M
Total Shareholders Equity i$706.90M$373.50M
Retained Earnings i$-1.50B$-585.35M
Property, Plant & Equipment i$55.58M$132.60M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TXGSDGR
Operating Cash Flow i$35.44M$153.46M
Capital Expenditures i$-1.89M$-596,000
Free Cash Flow i$32.46M$143.47M
Debt Repayment iN/A$-14,000
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTXGSDGR
Shares Short i17.35M10.52M
Short Ratio i7.5810.53
Short % of Float i0.22%0.26%
Average Daily Volume (10 Day) i2,746,6601,092,130
Average Daily Volume (90 Day) i2,469,4201,035,247
Shares Outstanding i122.29M72.87M
Float Shares i109.33M57.82M
% Held by Insiders i0.02%0.03%
% Held by Institutions i1.05%1.08%

Dividend Analysis & Yield Comparison: 10x Genomics vs Schrodinger

MetricTXGSDGR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A